Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

Precision Medicine Is the Future Of Healthcare When it comes to applied hard sciences, a source of progress has been more precise measurements and tools. This is especially true in physics and ...

However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

In its earnings release, ILMN widened its net loss for the full year 2024 to $1.2 billion from the $1.16 billion registered ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4 ...